ABCL AbCellera Biologics: רווח למניה בשנים עשר החודשים האחרונים

The AbCellera Biologics (ABCL) strategy relies on large-scale contracts with pharma behemoths without mergers. The net income per share value over the last 12 months confirms this trajectory, where -0.48 serves as the base parameter value. Growth is driven by AI-powered robotic molecule discovery and the synergy between elite immunologists and Silicon Valley engineers, creating unique intellectual capital.

To select high-quality assets, an investor must evaluate the actual efficiency of capital generation per share. This calculation correlates total annual net income with the total number of shares, which, combined with the AbCellera Biologics (ABCL) AI platform for antibody discovery, allows the TTM net income per share metric to determine the monetization rate of the company's scientific achievements.